GSK

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in 2020 asked manufacturers to pull Zantac off the market

HUL has said that it has an 'indemnification right' to recover the demand raised by the Income Tax department

The companies collectively are facing thousands of lawsuits against them in courts across the United States

The companies, which all sold Zantac at different times, argue that Medinilla should have granted their motion to block plaintiffs from presenting expert testimony that Zantac causes cancer

In 2019, some manufacturers and pharmacies halted Zantac sales after a chemical called NDMA, which is known to cause cancer, was detected in some pills

This form of asthma is characterised by high levels of eosinophils, which is a type of white blood cell.

Big drugmakers already face some 80,000 state suits from users of the drug who say their cancers were caused by Zantac contaminated with NDMA, the dangerous chemical Valisure discovered

GlaxoSmithKline Pharmaceuticals Ltd on Friday reported a 46 per cent increase in consolidated net profit at Rs 194.48 crore in the fourth quarter ended March 31, on the back of higher sales. The company had posted a net profit of Rs 133.43 crore in the corresponding quarter of the previous fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 929.8 crore as against Rs 787.45 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 691.41 crore as compared to Rs 635.54 crore in the same period a year ago. The board has recommended a dividend of Rs 32 per equity share on the face value of Rs 10 each for the year ended March 31, subject to approval of members at upcoming annual general meeting, the company said. For the fiscal ended March 31, 2024 net profit was at Rs 589.96 crore as compared to Rs 610.69 crore in the preceding year, the compa

Shares in GSK India closed up 0.3% ahead of results on Thursday, where the Nifty Pharma index closed down 0.03% today

US drugmaker Pfizers and British pharma major GSK are likely to face significant competition in the respiratory syncytial virus (RSV) vaccine market, according to a report on Tuesday

Shingrix is for the prevention of shingles or what is also known as herpes zoster and also post-herpetic neuralgia in people aged 50 and above, says GSK Pharmaceuticals MD Bhushan Akshikar

The takeover will bring GSK a cough medicine that's shown promising results in clinical trials and has advanced through much of the research process

GlaxoSmithKline Pharmaceuticals Ltd, the Indian unit of UK's GSK plc, reported a 9.5% rise in profit, in line with analysts' estimates, as a sharp drop in input costs more than offset revenue decline

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased 3 per cent to Rs 193 crore in the second quarter ended September. The drug maker had reported a net profit from continuing operations at Rs 187 crore in the July-September period of the previous fiscal. However, revenue from operations declined to Rs 906 crore in the second quarter of the current fiscal compared to Rs 916 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK India has delivered another quarter of strong performance in general medicines and specialty business, gaining market share. We hope to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth," GlaxoSmithKline Pharmaceuticals Managing Director Sridhar Venkatesh said. Vaccines business was impacted due to low vaccination rates as the overall market for the self-pay segment in which the company operates continues to decline, he ...

Brown, also 60, will join GSK in April and take up the job in May. She has extensive experience in the health and pharmaceutical industry.

Sanofi fell 13% on Thursday, taking its 2-day decline to 20%; GSK slid 6.9%

The companies point to the risk of new variants and waning immunity that could lead to an increase in demand for additional booster shots in some populations.

GlaxoSmithKline's IV drug for Covid-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most US cases, federal health regulators said

Sanofi-GSK's shot relies on a conventional protein-based approach, compared with the newer mRNA technology used in established Covid-19 vaccines from Pfizer-BioNTech and Moderna

Consumer protection regulator CCPA has passed an order against GlaxoSmithKline Consumer Healthcare Ltd directing it to discontinue advertisements of Sensodyne products in India for flouting norms.